| SAH | Sub-Arachnoid Hemorrhage; (뇌)지주막하출혈 ? Complications 1. Is... |
|---|---|
| AS-SCORE | age, stage of disease, physiological system involved, complications, response to therapy |
| CM | California mastitis [test]; calmodulin; capreomycin; carboxymethyl; cardiac murmur; cardiac muscle; ... |
| DCCT | diabetes control and complications trial |
| PAIC | procedures, alternatives, indications, and complications |
| rubella cataract | Embryopathic cataract secondary to intrauterine rubella infection. (05 Mar 2000) |
|---|---|
| rubella HI test | A haemagglutination inhibition (HI) test for rubella, often performed routinely as part of a prenatal workup of the pregnant woman; the presence of any detectable HI titre in the absence of disease indicates previous infection and immunity to reinfection; if HI antibody is undetected, the patient is considered potentially susceptible and is followed accordingly. See: haemagglutination inhibition. (05 Mar 2000) |
| rubella immunization | The standard MMR vaccine is given to prevent measles, mumps and rubella (german measles). The mmr vaccine is now given in two dosages. The first should be given at12-15 months of age. The second vaccination should be given at 4-6 years (or, alternatively, 11-12 years) of age. most colleges require proof of a second measles or mmr vaccination prior to entrance. Most children should receive mmr vaccinations. Exceptions may include children born with an inability to fight off infection, some children with cancer, on treatment with radiation or drugs for cancer, on long term steroids (cortisone). People with severe allergic reactions to eggs or the drug neomycin should probably avoid the mmr vaccine. Pregnant women should wait until after delivery before being immunised with mmr. People with HIV or aids should normally receive mmr vaccine. Measles, mumps, and rubella vaccines may be administered as individual shots, if necessary, or as a measles-rubella combination. (12 Dec 1998) |
| rubella retinopathy | Peripheral pigmentary retinal changes in congenital rubella, not affecting visual function. (05 Mar 2000) |
| rubella syndrome, congenital | Transplacental infection of the foetus with rubella usually in the first trimester of pregnancy, as a consequence of maternal infection, resulting in various developmental abnormalities in the newborn infant. They include cardiac and ocular lesions, deafness, microcephaly, mental retardation, and generalised growth retardation. (12 Dec 1998) |
| rubella vaccine | A live attenuated virus vaccine of duck embryo or human diploid cell tissue culture origin, used for routine immunization of children and for immunization of nonpregnant adolescent and adult females of childbearing age who are unimmunised and do not have serum antibodies to rubella. Children are usually immunised with measles-mumps-rubella combination vaccine. (12 Dec 1998) |
| rubella virus | The type (and only) species of rubivirus causing acute infection in humans, primarily children and young adults. Humans are the only natural host. A live, attenuated vaccine is available for prophylaxis. (12 Dec 1998) |
| rubella virus vaccine | A live virus vaccine prepared from duck embryo or human diploid cell culture infected with rubella virus; administered as a single subcutaneous injection. See: measles, mumps, and rubella vaccine. (05 Mar 2000) |
| congenital rubella syndrome | <syndrome> Foetal infection with rubella virus during the first trimester of pregnancy resulting in a series of congenital abnormalities including heart disease, deafness, and blindness. (05 Mar 2000) |
| immunization, rubella | See Immunization, MMR. (12 Dec 1998) |